5 sales and operations intern jobs found in Boston

Fusion Pharmaceuticals Fusion Pharmaceuticals, a member of the AstraZeneca Group , is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes but is not limited to: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. Fusion has multiple other pipeline programs that will soon be entering into early FIH trials. In addition, Fusion is pursuing combination programs between RCs and other therapeutic modalities including DNA Damage Response Inhibitors (DDRis) and...

Fusion Pharmaceuticals Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. In addition, Fusion is pursuing combination programs between RCs and DNA Damage Response Inhibitors (DDRis) and immune-oncology agents. Fusion has a fully operational Good...

Biogen About the Role Biogen is seeking an Immunology Thought Leader Liaison (TLL)Leadwith deep Rheumatology experience to support thelaunchreadiness and commercialization of our emerging Systemic Lupus Erythematosus (SLE) product. This field-based roleis responsible forexpanding Biogen's influence within the rheumatology community by engaging Key Medical Experts (KMEs), generating critical insights, and strengthening Biogen's position as a scientific and commercial leader in SLE. You will play a pivotal role in shaping strategy across disease education, advocacy, content development, congress presence, and advisory engagements, ensuring Biogen is fully prepared for future lupus launches. Key Responsibilities Thought Leader Engagement & Advocacy Drive KME strategy byidentifying, mapping, and cultivatingrelationships with established and emergingrheumatologyKMEs and influencers. Lead strategic national and regional engagements to expand Biogen'srheumatology...

Biogen About the Role Biogen is seeking an Immunology Thought Leader Liaison (TLL) Lead with deep Dermatology experience to support thelaunchreadiness and commercialization of our emerging Cutaneous Lupus Erythematosus (CLE) product. This field-based roleis responsible forexpanding Biogen's influence within the dermatology community by engaging Key Medical Experts (KMEs), generating critical insights, and strengthening Biogen's position as a scientific and commercial leader in CLE. You will play a pivotal role in shaping strategy across disease education, advocacy, content development, congress presence, and advisory engagements, ensuring Biogen is fully prepared for future lupus launches. Key Responsibilities Thought Leader Engagement & Advocacy Drive KME strategy byidentifying, mapping, and cultivating relationships with established and emerging dermatology KMEs and influencers. Lead strategic national and regional engagements to expand Biogen's dermatology...

Fusion Pharmaceuticals Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. In addition, Fusion is pursuing combination programs between RCs and DNA Damage Response Inhibitors (DDRis) and immune-oncology agents. Fusion has a fully operational Good Manufacturing Practice (GMP) compliant state-of-the-art radiopharmaceutical manufacturing facility to meet...